Audentes Therapeutics (BOLD) Misses Q1 EPS by 24c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of ($1.13), $0.24 worse than the analyst estimate of ($0.89).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance